Inventiva S.A.

EPA:IVA.PA

2.08 (EUR) • At close September 16, 2024
Bedrijfsnaam Inventiva S.A.
Symbool IVA.PA
Munteenheid EUR
Prijs 2.085
Beurswaarde 109,193,712
Dividendpercentage 0%
52-weken bereik 2.04 - 4.55
Industrie Biotechnology
Sector Healthcare
CEO Mr. Frederic Cren
Website https://www.inventivapharma.com

An error occurred while fetching data.

Over Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has

Vergelijkbare Aandelen

LNA Santé SA logo

LNA Santé SA

LNA.PA

23 EUR

Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA

HYL.BR

5.88 EUR

Cegedim SA logo

Cegedim SA

CGM.PA

12.5 EUR

Clínica Baviera, S.A. logo

Clínica Baviera, S.A.

CBAV.MC

32.9 EUR

Mithra Pharmaceuticals SA logo

Mithra Pharmaceuticals SA

MITRA.BR

0.216 EUR

AB Science S.A. logo

AB Science S.A.

AB.PA

1.032 EUR

Lumibird SA logo

Lumibird SA

LBIRD.PA

9.66 EUR

Guerbet SA logo

Guerbet SA

GBT.PA

35.35 EUR

Ion Beam Applications SA logo

Ion Beam Applications SA

IBAB.BR

13.46 EUR

ABIVAX Société Anonyme logo

ABIVAX Société Anonyme

ABVX.PA

10.38 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)